natgillin/translations-raw huggingface dataset:
By letter of 3 July 2008, Poland has submitted an application to the Commission for recognition of the Polski Rejestr Statków S.A. (hereinafter ‘PRS’) as a classification society within the meaning of the Directive.
Poljska je z dopisom z dne 3. julija 2008 Komisiji predložila prijavo za priznanje registra Polski Rejestr Statków S.A. (v nadaljnjem besedilu: PRS) kot klasifikacijskega zavoda v smislu direktive.
PRS has its headquarters in Poland.
PRS ima sedež na Poljskem.
With the application Poland has submitted the information and documentation needed to verify that the criteria for recognition are met.
Poljska je ob prijavi predložila vse potrebne informacije in dokumentacijo, da se preveri, ali so izpolnjena merila za priznanje.
A hearing was organised in the joint meeting of experts from the Member States of the European Union and the Central Commission for Navigation on the Rhine (hereinafter ‘CCNR’) on technical requirements for inland waterway vessels in April 2009, where the Poland authority and PRS gave presentations.
(3) Aprila 2009 je bil organiziran sestanek na skupnem srečanju strokovnjakov držav članic Evropske unije in Centralne komisije za plovbo po Renu (v nadaljnjem besedilu: CCNR) o tehničnih predpisih za plovila, namenjena za plovbo po celinskih plovnih poteh, kjer so poljski organi in PRS opravili predstavitve.
The secretariat of the CCNR has been consulted as referred to in Part II, paragraph 4, of Annex VII to Directive 2006/87/EC.
Opravljeno je bilo posvetovanje s sekretariatom CCNR, kot je navedeno v odstavku 4 dela II Priloge VII k Direktivi 2006/87/ES.
The Commission has assessed the compliance of PRS with the criteria of Part I of Annex VII to Directive 2006/87/EC and has concluded that PRS meets them,
Komisija je ocenila izpolnjevanje kriterijev iz dela I Priloge VII k Direktivi 2006/87/ES s strani PRS in ugotovila, da jih ta izpolnjuje –
The classification society PRS shall be recognised pursuant to Article 10 of Directive 2006/87/EC.
Klasifikacijski zavod PRS se prizna v skladu s členom 10 Direktive 2006/87/ES.
This Decision is addressed to the Member State(s) which have inland waterways as referred to in Article 1(1) of Directive 2006/87/EC and to the Polski Rejestr Statków (Polish Register of Shipping), al. gen.
Ta sklep je naslovljen na države članice, ki imajo celinske plovne poti iz člena 1(1) Direktive 2006/87/ES, in na Polski Rejestr Statków (Poljski ladijski register), Al. Gen.
Hallera 126, 80-416 Gdańsk, POLAND
Hallera 126, 80-416, Gdansk, Poljska
of 3 February 2012
z dne 3. februarja 2012
Having regard to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [1], and in particular Article 16f thereof,
ob upoštevanju Direktive 2001/83/ES Evropskega parlamenta in Sveta z dne 6. novembra 2001 o zakoniku Skupnosti o zdravilih za uporabo v humani medicini [1] ter zlasti člena 16f Direktive,
Thymus vulgaris L., Thymus zygis Loefl. ex L. can be considered as a herbal substance, a herbal preparation or a combination thereof within the meaning of Directive 2001/83/EC and it complies with the requirements set out in that Directive.
Thymus vulgaris L., Thymus zygis Loefl. ex L. se lahko šteje za rastlinsko snov, pripravek rastlinskega izvora ali kombinacijo iz njih v smislu Direktive 2001/83/ES in izpolnjuje zahteve iz navedene direktive.
It is therefore appropriate to include Thymus vulgaris L., Thymus zygis Loefl. ex L. in the list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products established by Commission Decision 2008/911/EC [2].
Zato je primerno, da se Thymus vulgaris L., Thymus zygis Loefl. ex L. vključi v z Odločbo Komisije 2008/911/ES [2] vzpostavljen seznam rastlinskih snovi, pripravkov in kombinacij iz njih za uporabo v tradicionalnih zdravilih rastlinskega izvora.
The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Medicinal Products for Human Use,
Ukrepi, predvideni s tem sklepom, so v skladu z mnenjem Stalnega odbora za zdravila za uporabo v humani medicini –
Annexes I and II to Decision 2008/911/EC are amended in accordance with the Annex to this Decision.
Prilogi I in II k Odločbi 2008/911/ES se spremenita v skladu s Prilogo k temu sklepu.
Done at Brussels, 3 February 2012.
V Bruslju, 3. februarja 2012
in Annex I, the following substance is inserted after Pimpinella anisum L.:
v Prilogi I se za vnosom Pimpinella anisum L. vstavi naslednja snov:
‘Thymus vulgaris L., Thymus zygis Loefl. ex L., aetheroleum’;
„Thymus vulgaris L., Thymus zygis Loefl. ex L., aetheroleum“;
in Annex II, the following is inserted after the entry on Pimpinella anisum L.:
v Prilogi II se za vnosom Pimpinella anisum L. vstavi naslednje:
‘COMMUNITY LIST ENTRY ON THYMUS VULGARIS L., THYMUS ZYGIS LOEFL.
„VPIS V SEZNAM SKUPNOSTI THYMUS VULGARIS L., THYMUS ZYGIS LOEFL.
Herbal preparation(s)
Pripravki(-ki) rastlinskega izvora
Essential oil obtained by steam distillation from the fresh flowering aerial parts of Thymus vulgaris L., Thymus zygis Loefl. ex L. or a mixture of both species
Terično olje, pridobljeno s parno destilacijo svežih, cvetočih nadzemnih delov Thymus vulgaris L., Thymus zygis Loefl. ex L. ali zmesi obeh vrst.
Indication(s)
Indikacija(-e)
Traditional herbal medicinal product for the relief of symptoms in coughs and colds.
Tradicionalno zdravilo rastlinskega izvora za lajšanje simptomov kašlja in prehlada.
The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use.
Izdelek je tradicionalno zdravilo rastlinskega izvora, namenjeno za uporabo pri navedeni indikaciji izključno na podlagi dolgotrajnih izkušenj.
European
Evropska.
Please see “Specified posology”
Glejte ‚Odmerjanje‘.
Adults and elderly
Odrasli in starejši bolniki
Cutaneous use: in liquid and semi-solid dosage forms in concentrations up to 10 %; apply up to 3 times daily.
Dermalna uporaba: v tekočih in poltrdnih farmacevtskih oblikah v koncentracijah do 10 %; nanesite do trikrat dnevno.
Use as bath additive: 0,007-0,025 g per litre.
Kot dodatek za kopel: 0,007–0,025 g na liter.
Adolescents
Mladostniki
Use as bath additive: 0,007-0,025 g per litre
Kot dodatek za kopel: 0,007–0,025 g na liter.
Children 6-12 years
Otroci, stari od 6 do 12 let
Use as bath additive: 0,0035-0,017 g per litre
Kot dodatek za kopel: 0,0035–0,017 g na liter.
Children 3-6 years
Otroci, stari od 3 do 6 let
Use as bath additive: 0,0017-0,0082 g per litre
Kot dodatek za kopel: 0,0017–0,0082 g na liter.
One bath every day or every second day.
Ena kopel na dan ali vsak drugi dan.
The cutaneous use in children and adolescents under 18 years of age is not recommended (see section “Special warnings and precaution for use”).
Dermalna uporaba pri otrocih in mladostnikih, mlajših od 18 let, ni priporočljiva (glejte poglavje ‚Posebna opozorila in previdnostni ukrepi‘).
The use as bath additive in children under 3 years of age is not recommended (see section “Special warnings and precaution for use”).
Uporaba kot dodatek za kopel pri otrocih, mlajših od 3 let, ni priporočljiva (glejte poglavje ‚Posebna opozorila in previdnostni ukrepi‘).
Cutaneous use: apply to the chest and the back.
Dermalna uporaba: nanesite na prsni koš in hrbet.
Use as a bath additive: recommended temperature of bath: 35-38 °C.
Kot dodatek za kopel: priporočena temperatura kopeli: 35–38 °C.
Duration of a bath: 10-20 minutes.
Trajanje kopeli: 10–20 minut.
If the symptoms persist longer than 1 week, a doctor or a qualified health care practitioner should be consulted.
Če simptomi po 1 tednu ne popustijo, se je treba posvetovati z zdravnikom ali usposobljenim zdravstvenim delavcem.
Use as bath additive:
Kot dodatek za kopel:
Full baths are contraindicated in cases of open wounds, large skin injuries, acute skin diseases, high fever, severe infections, severe circulatory disturbances and cardiac insufficiency.
Kopeli celega telesa se kontraindicirane v primerih odprtih ran, večjih poškodb kože, akutnih bolezni kože, zvišane telesne temperature, hudih okužb, hudih motenj krvnega obtoka in srčne insuficience.
Cutaneous use:
Dermalna uporaba:
Like other essential oils Thyme oil should not be applied to the face particularly in the nasal area of babies and infants under the age of 2 years because of the risk of a laryngospasm.
Timijanovega olja se tako kot tudi drugih eteričnih olj ne sme nanašati na obraz (zlasti okrog nosu) dojenčkov in majhnih otrok, mlajših od 2 let, zaradi nevarnosti laringospazma (krča glotisa).
When dyspnoea, fever or purulent sputum occurs, a doctor or a qualified health care practitioner should be consulted.
Če se pojavijo težave z dihanjem, zvišana telesna temperatura ali gnojen izpljunek, se je treba posvetovati z zdravnikom ali usposobljenim zdravstvenim delavcem.
The use in children and adolescents under 18 years of age is not recommended due to lack of adequate data.
Zaradi pomanjkanja ustreznih podatkov uporaba pri otrocih in mladostnikih, mlajših od 18 let, ni priporočljiva.
The use in children under 3 years of age is not recommended because medical advice should be sought and due to lack of adequate data.
Zaradi pomanjkanja ustreznih podatkov in ker se je treba posvetovati z zdravnikom, uporaba pri otrocih, mlajših od 3 let, ni priporočljiva.
In cases of hypertension, a full bath should be used with caution.
V primeru povišanega krvnega tlaka je treba kopeli celega telesa uporabljati previdno.
Hypersensitivity reactions and skin irritation have been observed.
Poročali so o preobčutljivostnih reakcijah in draženju kože.
Pharmaceutical particulars [If necessary]
Farmacevtski podatki (če so potrebni)
Pharmacological effects or efficacy plausible on the basis of long-standing use and experience [If necessary for the safe use of the product]
Verjetni farmakološki učinki ali učinkovitost, ugotovljeni na podlagi dolgotrajne uporabe in izkušenj (če je potrebno za varno uporabo zdravila)
Not applicable.’
Navedba smiselno ni potrebna.“
Vitis vinifera L. can be considered as a herbal substance, a herbal preparation or a combination thereof within the meaning of Directive 2001/83/EC and it complies with the requirements set out in that Directive.
Vitis vinifera L. se lahko šteje za rastlinsko snov, pripravek rastlinskega izvora ali kombinacijo iz njih v smislu Direktive 2001/83/ES in izpolnjuje zahteve iz navedene direktive.
It is therefore appropriate to include Vitis vinifera L. in the list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products established by Commission Decision 2008/911/EC [2].
Zato je primerno, da se Vitis vinifera L. vključi v z Odločbo Komisije 2008/911/ES [2] vzpostavljen seznam rastlinskih snovi, pripravkov in kombinacij iz njih za uporabo v tradicionalnih zdravilih rastlinskega izvora.
in Annex I, the following substance is inserted after Thymus vulgaris L., Thymus zygis Loefl. ex L., aetheroleum:
v Prilogi I se za vnosom Thymus vulgaris L., Thymus zygis Loefl. ex L., aetheroleum vstavi naslednja snov:
‘Vitis vinifera L., folium’
„Vitis vinifera L., folium“;
in Annex II, the following is inserted after the entry on Thymus vulgaris L., Thymus zygis Loefl. ex L.:
v Prilogi II se za vnosom Thymus vulgaris L., Thymus zygis Loefl. ex L. vstavi naslednje:
‘COMMUNITY LIST ENTRY ON VITIS VINIFERA L., FOLIUM
„VPIS V SEZNAM SKUPNOSTI VITIS VINIFERA L., FOLIUM
Grapevine leafCommon name of herbal substance in all EU official languages
List vinske trteSplošno ime rastlinske snovi v vseh uradnih jezikih EU
Herbal preparation(s)
Pripravek(-ki) rastlinskega izvora
Soft extract (2.5-4:1; extraction solvent water)
Gosti ekstrakt (2,5–4:1; ekstrakcijsko topilo: voda)
Traditional herbal medicinal product to relieve symptoms of discomfort and heaviness of legs related to minor venous circulatory disturbances.
Tradicionalno zdravilo rastlinskega izvora, ki se uporablja za lajšanje simptomov pri težavah z nogami in občutku težkih nog, nastalih zaradi manjših motenj v venskem obtoku.
The product is a traditional herbal medicinal product for use in specified indication exclusively based upon long-standing use.
Izdelek je tradicionalno zdravilo rastlinskega izvora, namenjeno za uporabo pri navedeni indikaciji izključno na podlagi dolgotrajnih izkušenj.
Soft extract (2.5-4:1; extraction solvent water) in a cream base (10 g contain 282 mg soft extract).
Gosti ekstrakt (2,5–4:1; ekstrakcijsko topilo: voda) v kremni bazi (10 g vsebuje 282 mg gostega ekstrakta).
Apply a thin layer on the affected area 1-3 times daily.
Na prizadeto območje se nanese tanka plast 1- do 3-krat dnevno.
The use in children and adolescents under 18 years of age is not recommended (see section “Special warnings and precautions for use”).
Uporaba pri otrocih in mladostnikih, mlajših od 18 let, ni priporočljiva (glejte poglavje ‚Posebna opozorila in previdnostni ukrepi‘).
The recommended duration of use is 4 weeks.
Priporočeno trajanje uporabe je 4 tedne.
If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
Če simptomi med uporabo zdravila ne popustijo po 2 tednih, se je treba posvetovati z zdravnikom ali usposobljenim zdravstvenim delavcem.
If there is inflammation of the skin, thrombophlebitis or subcutaneous induration, severe pain, ulcers, sudden swelling of one or both legs, cardiac or renal insufficiency, a doctor should be consulted.
Če gre za vnetje kože, tromboflebitis ali podkožni strdek, močno bolečino, razjede, nenadno zatekanje ene ali obeh nog ter srčno ali ledvično insuficienco, se je treba posvetovati z zdravnikom.
The product should not be used on broken skin, around the eyes or on mucous membranes.
Izdelek se ne sme uporabljati na poškodovani koži, okrog oči ali na sluznici.
In the absence of sufficient safety data, the use in children and adolescents below 18 years of age is not recommended.
Zaradi pomanjkanja ustreznih podatkov uporaba pri otrocih in mladostnikih, mlajših od 18 let, ni priporočljiva.
Contact allergy and/or hypersensitivity reactions of the skin (itching and erythema, urticaria) have been reported.
Poročali so o kontaktnih alergijah in/ali preobčutljivostnih reakcijah kože (srbenju in kožni rdečini, urtikariji).
The material complies with the monograph of the Pharmacopée Française X., 1996.’
Gradivo je skladno z monografijo Francoske farmakopeje X., 1996.“
amending Decisions 2007/305/EC, 2007/306/EC and 2007/307/EC as regards the tolerance period for traces of Ms1xRf1 (ACS-BNØØ4-7xACS-BNØØ1-4) hybrid oilseed rape, Ms1xRf2 (ACS-BNØØ4-7xACS-BNØØ2-5) hybrid oilseed rape and Topas 19/2 (ACS-BNØØ7-1) oilseed rape, as well as of their derived products
o spremembi odločb 2007/305/ES, 2007/306/ES in 2007/307/ES v zvezi s prehodnim obdobjem za sledove hibridne oljne ogrščice Ms1xRf1 (ACS-BNØØ4-7xACS-BNØØ1-4), hibridne oljne ogrščice Ms1xRf2 (ACS-BNØØ4-7xACS-BNØØ2-5) in oljne ogrščice Topas 19/2 (ACS-BNØØ7-1) ter proizvodov iz njih
Having regard to Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified food and feed [1], and in particular Articles 8(6) and 20(6) thereof,
ob upoštevanju Uredbe (ES) št. 1829/2003 Evropskega parlamenta in Sveta z dne 22. septembra 2003 o gensko spremenjenih živilih in krmi [1] ter zlasti člena 8(6) in člena 20(6) Uredbe,
Commission Decisions 2007/305/EC [2], 2007/306/EC [3] and 2007/307/EC [4] set out the rules for the withdrawal from the market of the following genetically modified material (‘the GM material’): Ms1xRf1 (ACS-BNØØ4-7xACS-BNØØ1-4) hybrid oilseed rape, Ms1xRf2 (ACS-BNØØ4-7xACS-BNØØ2-5) hybrid oilseed rape and Topas 19/2 (ACS-BNØØ7-1) oilseed rape, as well as their derived products.
Odločbe Komisije 2007/305/ES [2], 2007/306/ES [3] in 2007/307/ES [4] so določile pravila o umiku naslednjega gensko spremenjenega materiala s trga: hibridne oljne ogrščice Ms1xRf1 (ACS-BNØØ4-7xACS-BNØØ1-4), hibridne oljne ogrščice Ms1xRf2 (ACS-BNØØ4-7xACS-BNØØ2-5) in oljne ogrščice Topas 19/2 (ACS-BNØØ7-1) ter proizvodov iz njih.
Those Decisions have been adopted after the notifier of the GM material had indicated to the Commission that it had no intention to submit an application for renewal of the authorisation of that material in accordance with the first subparagraph of Article 8(4), Article 11, Article 20(4) and Article 23 of Regulation (EC) No 1829/2003.
Navedene odločbe so bile sprejete, potem ko je prijavitelj gensko spremenjenega materiala Komisiji sporočil, da ne namerava oddati vloge za obnovitev odobritve za navedeni material v skladu s prvim pododstavkom člena 8(4), členom 11, členom 20(4) in členom 23 Uredbe (ES) št. 1829/2003.
All three Decisions provide for a transitional period of time of 5 years, during which food and feed containing the GM material are allowed to be placed on the market, in accordance with Article 4(2) or Article 16(2) of the Regulation, subject to a number of conditions.
Vse tri odločbe določajo prehodno obdobje petih let, v katerih je ob izpolnjevanju več pogojev dovoljeno na trg dati živila in krmo, ki vsebujejo gensko spremenjeni material v skladu s členom 4(2) ali členom 16(2) Uredbe.
The Decisions require in particular that the presence of the GM material in food and feed does not exceed a threshold of 0,9 % and that the presence of this GM material be adventitious or technically unavoidable.
Odločbe zlasti zahtevajo, da prisotnost gensko spremenjenega materiala v živilih in krmi ne presega praga 0,9 % ter da je prisotnost tega gensko spremenjenega materiala naključna ali tehnično neizogibna.
The purpose of the transitional period is to take into consideration the fact that minute traces of the GM material can be present in the food and feed chain some time after the notifier has decided to stop selling seeds derived from the GMO, even if the notifier has taken all measures to avoid that presence.
Namen prehodnega obdobja je upoštevati dejstvo, da lahko minimalni sledovi gensko spremenjenega materiala ostanejo v prehranski verigi ljudi in živali nekaj časa po tem, ko se prijavitelj odloči, da preneha prodajati seme iz gensko spremenjenih organizmov, čeprav prijavitelj sprejme vse ukrepe, da prepreči navedeno prisotnost.
Decisions 2007/305/EC and 2007/306/EC also set out a series of measures that the notifier has to take to ensure the effective withdrawal from the market of Ms1xRf1 (ACS-BNØØ4-7xACS-BNØØ1-4) hybrid oilseed rape, Ms1xRf2 (ACS-BNØØ4-7xACS-BNØØ2-5) hybrid oilseed rape and their derived products.
Odločbi 2007/305/ES in 2007/306/ES tudi določata vrsto ukrepov, ki jih prijavitelj mora sprejeti, da se zagotovi učinkovit umik hibridne oljne ogrščice Ms1xRf1 (ACS-BNØØ4-7xACS-BNØØ1-4), hibridne oljne ogrščice Ms1xRf2 (ACS-BNØØ4-7xACS-BNØØ2-5) ter proizvodov iz njiju s trga.
In the absence of experience or concrete data on the time needed to ensure a complete withdrawal from the market of the GM material, the tolerated level of presence of that material and the time needed to ensure total withdrawal from the food and feed chains provided for in Decisions 2007/305/EC, 2007/306/EC and 2007/307/EC were set on the basis of data available at this time and results of testing by stakeholders.
Zaradi pomanjkanja izkušenj ali konkretnih podatkov o času, potrebnem za zagotovitev popolnega umika gensko spremenjenega materiala s trga, sta bili dopustna raven prisotnosti navedenega materiala in potreben čas za zagotovitev popolnega umika iz prehranske verige ljudi in živali določena v odločbah 2007/305/ES, 2007/306/ES in 2007/307/ES na podlagi trenutno razpoložljivih podatkov in rezultatov preskusov, ki so jih opravile zainteresirane strani.
In accordance with the requirements of Decisions 2007/305/EC and 2007/306/EC, the authorisation holder submitted detailed reports in October 2007 and November 2011 on the implementation of discontinuation measures for the above GM oilseed rape events.
V skladu z zahtevami odločb 2007/305/ES in 2007/306/ES je imetnik dovoljenja predložil podrobni poročili oktobra 2007 in novembra 2011 o izvajanju ukrepov za prenehanje zagotavljanja navedene gensko spremenjene oljne ogrščice.
These reports outline past and current measures which have been implemented by the authorisation holder in accordance with the abovementioned decisions to ensure the removal of this GM material from the market.
Navedeni poročili opisujeta pretekle in sedanje ukrepe, ki jih je izvajal imetnik dovoljenja v skladu z navedenimi odločbami, da se zagotovi umik tega gensko spremenjenega materiala s trga.
These include, among others, steps taken to inform commercial operators in the EU of the discontinued status of this GM material, the implementation of a series of measures to ensure the recall and destruction of remaining commercial seed stock, the conclusion of agreements with all third parties involved in the commercialisation of this GM material to ensure that the seed from this GM material is either sent back to the authorisation holder or is effectively destroyed, the actions undertaken to ensure the deregistration of registered varieties of the event concerned from the national seed catalogue and the implementation of an in-house program based on a quality assurance process to avoid the presence of these GM events in breeding and seed production.
Ti med drugim vključujejo ukrepe za obvestitev gospodarskih subjektov v EU o prenehanju zagotavljanja tega gensko spremenjenega materiala, izvajanje vrste ukrepov za zagotovitev umika in uničenja preostalih trgovskih zalog semena, ki jih imajo subjekti, sklenitev sporazumov z vsemi tretjimi strankami, ki so vključene v trženje tega gensko spremenjenega materiala, za zagotovitev, da se seme iz tega gensko spremenjenega materiala vrne imetniku dovoljenja ali v celoti uniči, ukrepe za zagotovitev izbrisa vpisanih sort zadevnega materiala z nacionalnih sortnih list ter izvajanje programa v podjetju na podlagi postopka za zagotavljanje kakovosti, da se prepreči prisotnost tega gensko spremenjenega materiala pri gojenju in proizvodnji semena.
Recent test results notified by stakeholders to the Commission show that the measures undertaken by the authorisation holder have allowed the removal of nearly all the GM material from the market.
Nedavni rezultati preskusov, ki so jih zainteresirane strani sporočile Komisiji, kažejo, da so ukrepi, ki jih je sprejel imetnik dovoljenja, omogočili umik skoraj vsega gensko spremenjenega materiala s trga.
However, these results also show that minute traces (< 0,1 %) of the GM material may still be present in the food or feed chain at the end of the transitional period set out in Decisions 2007/305/EC, 2007/306/EC and 2007/307/EC.
Vendar ti rezultati tudi kažejo, da bodo minimalni sledovi gensko spremenjenega materiala (< 0,1 %) morda ostali v prehranski verigi ljudi in živali ob koncu prehodnega obdobja, določenega v odločbah 2007/305/ES, 2007/306/ES in 2007/307/ES.
The presence of remaining traces after the expiry date set out in these decisions, despite the measures undertaken by the notifier, can be explained by the biology of oilseed rape which can remain dormant for long periods as well as by the farm practices which have been employed to harvest the seed and resulting accidental spillage, the level of which was difficult to estimate at the date of adoption of the three abovementioned Decisions.
Prisotnost preostalih sledi po preteku roka, določenega v teh odločbah, navkljub ukrepom, ki jih je sprejel prijavitelj, je mogoče pojasniti z biologijo oljne ogrščice, ki je lahko dolgo speča, ter s kmetijskimi praksami, uporabljenimi za spravilo semena, in posledičnim nenamernim razsutjem, pri čemer je bilo raven prisotnosti sledi težko oceniti na dan sprejetja treh navedenih odločb.